ES2178207T3 - Nuevos derivados de triptolida utiles en el tratamiento de enfermedades autoinmunes. - Google Patents

Nuevos derivados de triptolida utiles en el tratamiento de enfermedades autoinmunes.

Info

Publication number
ES2178207T3
ES2178207T3 ES98919928T ES98919928T ES2178207T3 ES 2178207 T3 ES2178207 T3 ES 2178207T3 ES 98919928 T ES98919928 T ES 98919928T ES 98919928 T ES98919928 T ES 98919928T ES 2178207 T3 ES2178207 T3 ES 2178207T3
Authority
ES
Spain
Prior art keywords
treatment
autoimmune diseases
new useful
triptolide derivatives
nco2h
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98919928T
Other languages
English (en)
Inventor
Michael J Jung
Mahinda Wickramaratne
Michael Hepperle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2178207T3 publication Critical patent/ES2178207T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto de fórmula: **(Fórmula)** en la que R1 y R2 son cada uno independientemente H u - OR5; R3 es H, - C(=O)(CH2)nCO2H o un aminoácido seleccionado del grupo formado por alanina, arginina, asparagina, ácido aspártico, cisteína, glutamina, ácido glutámico, glicina, histidina, isoleucina, leucina, lisina, metionina, fenilalanina, prolina, serina, treonina, triptófano, tirosina y valina; R4 es H u - OH; R5 es H, - C(=O)(CH2)nCO2H o un aminoácido seleccionado del grupo formado por alanina, arginina, asparagina, ácido aspártico, cisteína, glutamina, ácido glutámico, glicina, histidina, isoleucina, leucina, lisina, metionina, fenilalanina, prolina, serina, treonina, triptófano, tirosina y valina; n es el número entero 2, 3, 4, 5 ó 6; y sus estereoisómeros, enantiómeros y sales farmacéuticamente aceptables; con la condición de que R1 y R2 son H cuando R3 no es H.
ES98919928T 1997-05-23 1998-04-27 Nuevos derivados de triptolida utiles en el tratamiento de enfermedades autoinmunes. Expired - Lifetime ES2178207T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86248897A 1997-05-23 1997-05-23

Publications (1)

Publication Number Publication Date
ES2178207T3 true ES2178207T3 (es) 2002-12-16

Family

ID=25338616

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98919928T Expired - Lifetime ES2178207T3 (es) 1997-05-23 1998-04-27 Nuevos derivados de triptolida utiles en el tratamiento de enfermedades autoinmunes.

Country Status (20)

Country Link
EP (1) EP0983275B1 (es)
JP (1) JP2001525851A (es)
KR (1) KR20010012822A (es)
CN (1) CN1257507A (es)
AR (1) AR012723A1 (es)
AT (1) ATE222910T1 (es)
AU (1) AU741917B2 (es)
BR (1) BR9809678A (es)
CA (1) CA2287977A1 (es)
DE (1) DE69807466T2 (es)
DK (1) DK0983275T3 (es)
ES (1) ES2178207T3 (es)
HU (1) HUP0003398A3 (es)
IL (1) IL133088A0 (es)
NO (1) NO995723L (es)
NZ (1) NZ500762A (es)
PT (1) PT983275E (es)
TW (1) TW434235B (es)
WO (1) WO1998052951A1 (es)
ZA (1) ZA984174B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329148B1 (en) 1999-02-16 2001-12-11 The Board Of Trustees Of The Leland Stanford University Combined therapy of diterpenoid triepoxides and death domain receptor ligands for synergistic killing of tumor cells
US6569893B2 (en) * 2001-03-15 2003-05-27 Pharmagenesis, Inc. Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents
JP4680589B2 (ja) * 2002-05-31 2011-05-11 ファーマジェネシス， インコーポレイテッド アポトーシスおよび免疫抑制の調節のためのトリプトリド誘導体
CN100398544C (zh) * 2002-09-18 2008-07-02 成都达远药物有限公司 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用
JP2006513209A (ja) * 2002-12-17 2006-04-20 ファーマジェネシス， インコーポレイテッド 免疫調節因子および抗癌剤としてのトリプトライド誘導体
CN1223595C (zh) 2002-12-27 2005-10-19 中国科学院上海药物研究所 雷公藤内酯醇衍生物及其应用
US6943259B2 (en) * 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
US7820834B2 (en) 2003-12-24 2010-10-26 Pharmagenesis, Inc. Triptolide 5,6-derivatives as immunomodulators and anticancer agents
EP1722806A4 (en) 2004-02-09 2009-09-16 Pharmagenesis Inc METHOD OF ISOLATING TRIPTOLIDE COMPOUNDS FROM TRIPTERYGIUM WILFORDII
ES2385716T3 (es) 2004-03-02 2012-07-30 Pharmagenesis, Inc. Derivados en el anillo de lactona de triptolida como inmunomoduladores y agentes anticáncer
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US8617906B2 (en) 2004-10-13 2013-12-31 Pharmagenesis, Inc. Identification and screening of triptolide target molecules
AU2010210594B2 (en) * 2009-02-05 2015-02-12 Pharmagenesis, Inc. Triptolide C-ring derivatives as anticancer agents and immune modulators
CN107207525B (zh) * 2015-10-29 2018-11-27 杭州卫本药业有限公司 C14-位羟基酯化的雷公藤甲素氨基酸衍生物、及其制备方法和应用
CN114716503B (zh) * 2022-03-23 2024-03-12 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种雷公藤氯内酯醇的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005108A (en) * 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
US5430054A (en) * 1989-12-22 1995-07-04 Jiangsu Family Planning Institute Preparation methods of diterpene lactone compounds and application of the same to antifertility
US5663335A (en) * 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods

Also Published As

Publication number Publication date
DK0983275T3 (da) 2002-12-23
BR9809678A (pt) 2000-07-11
CA2287977A1 (en) 1998-11-26
KR20010012822A (ko) 2001-02-26
DE69807466D1 (de) 2002-10-02
ATE222910T1 (de) 2002-09-15
AR012723A1 (es) 2000-11-08
JP2001525851A (ja) 2001-12-11
HK1026096A1 (en) 2000-12-01
HUP0003398A2 (en) 2001-03-28
AU7260798A (en) 1998-12-11
WO1998052951A1 (en) 1998-11-26
NO995723D0 (no) 1999-11-22
ZA984174B (en) 1998-11-23
AU741917B2 (en) 2001-12-13
EP0983275A1 (en) 2000-03-08
TW434235B (en) 2001-05-16
CN1257507A (zh) 2000-06-21
PT983275E (pt) 2003-01-31
HUP0003398A3 (en) 2001-09-28
EP0983275B1 (en) 2002-08-28
DE69807466T2 (de) 2003-04-24
IL133088A0 (en) 2001-03-19
NZ500762A (en) 2001-08-31
NO995723L (no) 2000-01-21

Similar Documents

Publication Publication Date Title
ES2178207T3 (es) Nuevos derivados de triptolida utiles en el tratamiento de enfermedades autoinmunes.
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
GB2382346A (en) Method of synthesizing diketopiperazines
DE69713112D1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
ES2113606T3 (es) Cetonas peptidicas como inhibidores de la enzima convertidora de la interleuquina-1beta.
EP0873754A4 (en) AMINO ACID COMPOSITIONS
NZ334906A (en) A sulphonamido pentanoic acid derivative useful as an interleukin-1-beta converting enzyme inhibitor
MX2022007881A (es) Proteina f mutante del virus sincitial respiratorio (rsv) y usos de la misma.
ITTO20030789A1 (it) Composizione a base di amino acidi per il trattamento
DK0552240T3 (da) Ny metode til behandling af depression
DK0896615T3 (da) Peptid fra opløselig form af acetylcholinesterase, der er aktivt som calcium-kanal-modulator
HU9201470D0 (en) Process for the production of new polypeptides that show affininty towards lipoposaccharides
KR970005043B1 (en) Tumor necrosis factor alpha muteins
ITRM910189A1 (it) Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono
DE60230621D1 (de) Essbare bzw. trinkbare sowie medizinisch verwendbare, die körpertemperatur erhöhende aminosäurezusammensetzung
KR950005320A (ko) 위장 운동 자극 활성을 가지는 폴리펩티드
ES487926A0 (es) Procedimiento de fabricacion de compuestos que resultan de la fijacion de muramilpeptidos, sus homologos y derivados
ES2134474T3 (es) Peptidos utilizados como agentes terapeuticos para el tratamiento de enfermedades autoinmunitarias.
ES2088239T3 (es) Nuevos derivados peptidicos, procedimiento de preparacion y aplicacion como medicamentos de estos nuevos derivados.
RU94024392A (ru) Минерально-аминокислотный концентрат
DE69133010D1 (de) Zur steigerung der antitumorimmunität wirksames proteoglykan (g009)
DE69911689D1 (de) Verfahren zur Herstellung von S-Aryl-L-cystein und Derivate
ATE92078T1 (de) Pharmakologisch aktive peptide.
ES2135389T3 (es) Antagonistas de endotelina.
CO5640144A2 (es) Analogos de 1-desamino-8-d-arginina vasopresina